In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Marc Bonaca
Speaker
Marc Bonaca
Marc Bonaca Marc Bonaca

University of Colorado, Aurora (United States of America)

Specialities : Coronary Artery Disease Chronic , Peripheral Vascular and Cerebrovascular Disease, Diseases of the aorta

25 presentations from this speaker

Protecting the patient undergoing lower extremity revascularization for symptomatic PAD.

Event : ESC Congress 2020

  • Session : Towards a new standard of care in coronary and peripheral artery disease: from trial results to guidelines and beyond
  • Speaker : M Bonaca (Boston,US)
  • Sponsored by Bayer AG

THEMIS-PAD Ticagrelor in Patients with and without Peripheral Artery Disease

Event : ESC Congress 2020

  • Session : Late-Breaking Science in Cardiovascular Pharmacotherapy
  • Speaker : M Bonaca (Boston,US)

Discussion

Event : ESC Congress 2019

  • Session : Confronting cardiovascular risk in patients with diabetes - Spotlight on dual antiplatelet therapy (EBAC Accredited)
  • Speaker : M Bonaca (Boston,US), P Steg (Paris,FR), H Darius (Berlin,DE), KK Ray (London,GB)
  • Supported by an unrestricted educational grant from AstraZeneca

Duration of DAPT should be beyond 1 year post acute coronary syndrome - PRO.

Event : ESC Congress 2019

  • Session : Controversies in anti-platelet therapy
  • Speaker : M Bonaca (Boston,US)

Prevent thrombosis is key to lowering the risk post acute coronary syndromes

Event : ESC Congress 2019

  • Session : Key issues in risk management after acute coronary syndromes
  • Speaker : M Bonaca (Boston,US)

Questions and answers

Event : ESC Congress 2019

  • Session : Spotlight on the effects of SGLT2 inhibition in heart failure (EBAC accredited)
  • Speaker : F Ruschitzka (Zurich,CH), M Bonaca (Boston,US), S Verma (Toronto,CA), M Kosiborod (Kansas,US)
  • Supported by an unrestricted educational grant from AstraZeneca

Summary and close

Event : ESC Congress 2019

  • Session : Confronting cardiovascular risk in patients with diabetes - Spotlight on dual antiplatelet therapy (EBAC Accredited)
  • Speaker : M Bonaca (Boston,US)
  • Supported by an unrestricted educational grant from AstraZeneca

The clinical impact of SGLT2 inhibitor cardiovascular outcomes trials

Event : ESC Congress 2019

  • Session : Spotlight on the effects of SGLT2 inhibition in heart failure (EBAC accredited)
  • Speaker : M Bonaca (Boston,US)
  • Supported by an unrestricted educational grant from AstraZeneca

Audience question and answer session.

Event : ESC Congress 2018

  • Session : Precision medicine in coronary patients: enhanced risk identification and treatment
  • Speaker : GM De Ferrari (Pavia,IT), M Bonaca (Boston,US), F Mach (Geneva,CH)
  • Sponsored by MSD

Call to action, pharmacotherapeutic approaches to reducing long term risk: right patient, right treatment.

Event : ESC Congress 2018

  • Session : Residual cardiovascular risk after an acute coronary syndrome: identifying, stratifying and managing patients at long term risk of atherothrombotic cardiovascular events (EBAC Accredited)
  • Speaker : M Bonaca (Boston,US)
  • Sponsored by AstraZeneca

Discussion - Residual cardiovascular risk after an acute coronary syndrome: identifying, stratifying and managing patients at long term risk of atherothrombotic cardiovascular events.

Event : ESC Congress 2018

  • Session : Residual cardiovascular risk after an acute coronary syndrome: identifying, stratifying and managing patients at long term risk of atherothrombotic cardiovascular events (EBAC Accredited)
  • Speaker : S James (Uppsala,SE), DJ Angiolillo (Jacksonville,US), SJ Nicholls (Adelaide,AU), M Bonaca (Boston,US)
  • Sponsored by AstraZeneca

Latest insight into risk identification and potential implications for futuretreatment standards.

Event : ESC Congress 2018

  • Session : Precision medicine in coronary patients: enhanced risk identification and treatment
  • Speaker : M Bonaca (Boston,US), F Mach (Geneva,CH)
  • Sponsored by MSD

Optimal management of long term cardiovascular risk in diabetic patients with established coronary artery disease: a clinical case study.

Event : ESC Congress 2018

  • Session : Residual cardiovascular risk after an acute coronary syndrome: identifying, stratifying and managing patients at long term risk of atherothrombotic cardiovascular events (EBAC Accredited)
  • Speaker : M Bonaca (Boston,US)
  • Sponsored by AstraZeneca

A clinician's perspective on recent guidelines in clinical practice.

Event : ESC Congress 2017

  • Session : State-of-the-art lipid treatment in coronary patients in 2017
  • Speaker : M Bonaca (Boston,US)
  • Sponsored by MSD

Audience Q&A - State-of-the-art-lipid treatment in coronary patients in 2017.

Event : ESC Congress 2017

  • Session : State-of-the-art lipid treatment in coronary patients in 2017
  • Speaker : M Bonaca (Boston,US), E Braunwald (Boston,US), F Mach (Geneva,CH)
  • Sponsored by MSD

A clinical case study - Continuing the patient journey back to primary care.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : M Bonaca (Boston,US)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Discussion - Optimising antiplatelet therapy from first medical contact to discharge.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : D Capodanno (Catania,IT), C Hamm (Bad Nauheim,DE), S James (Uppsala,SE), P Steg (Paris,FR), M Bonaca (Boston,US)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Discussion - The patient journey after an acute coronary syndrome - A clinical case study.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : D Capodanno (Catania,IT), C Hamm (Bad Nauheim,DE), S James (Uppsala,SE), P Steg (Paris,FR), M Bonaca (Boston,US)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Discussion - Who, when and why - The rationale to treat beyond 12 months.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : D Capodanno (Catania,IT), C Hamm (Bad Nauheim,DE), S James (Uppsala,SE), P Steg (Paris,FR), M Bonaca (Boston,US)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Open questions - The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : P Steg (Paris,FR), S James (Uppsala,SE), M Bonaca (Boston,US)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Prevention of First Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54

Event : ESC Congress 2016

  • Session : Clinical Trial Update Platelet therapy
  • Speaker : M Bonaca (Boston,US)

Who, when and why - The rationale to treat beyond 12 months.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : M Bonaca (Boston,US)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal

Event : ESC Congress 2015

  • Session : Clinical Trial Update II - Antiplatelet therapy
  • Speaker : M Bonaca (Boston,US)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are